Compare TGT & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGT | RMD |
|---|---|---|
| Founded | 1902 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.7B | 36.4B |
| IPO Year | N/A | 1995 |
| Metric | TGT | RMD |
|---|---|---|
| Price | $98.17 | $242.45 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 27 | 13 |
| Target Price | $101.04 | ★ $289.09 |
| AVG Volume (30 Days) | ★ 7.0M | 924.4K |
| Earning Date | 11-19-2025 | 01-29-2026 |
| Dividend Yield | ★ 4.58% | 0.98% |
| EPS Growth | N/A | ★ 29.59 |
| EPS | 8.25 | ★ 9.77 |
| Revenue | ★ $105,242,000,000.00 | $5,257,400,000.00 |
| Revenue This Year | N/A | $9.85 |
| Revenue Next Year | $1.80 | $7.36 |
| P/E Ratio | ★ $12.06 | $25.05 |
| Revenue Growth | N/A | ★ 9.36 |
| 52 Week Low | $83.44 | $199.92 |
| 52 Week High | $145.08 | $293.81 |
| Indicator | TGT | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 59.84 | 39.71 |
| Support Level | $93.77 | $241.66 |
| Resistance Level | $103.03 | $245.99 |
| Average True Range (ATR) | 2.71 | 4.68 |
| MACD | 0.13 | -0.36 |
| Stochastic Oscillator | 54.66 | 4.28 |
Target's start dates back to 1962, but now it is one of the largest discount retailers in the United States (where it derives all of its sales), operating just under 2,000 stores and generating over $106 billion in fiscal 2024 sales. The company offers a broad assortment of merchandise across categories including apparel and accessories (16% of fiscal 2024 revenue), beauty and household essentials (30%), food and beverage (23%), hardlines (15%), as well as home furnishings (16%). Target's model is anchored in its physical store base, which fulfills more than 97% of sales. Around 30% of sales are derived from its own private-label brands.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.